1.1Intermittent cooling for pain relief
A pump circulates chilled water through channels in a flexible pad placed over a dry insulating layer. Intermittent cooling lowers superficial tissue temperature and slows sensory nerve conduction.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A pump circulates chilled water through channels in a flexible pad placed over a dry insulating layer. Intermittent cooling lowers superficial tissue temperature and slows sensory nerve conduction.
A padded brace uses adjustable straps and rigid stays to restrict movement at the affected joint. Restricting joint excursion limits stretch and loading of nearby muscles during repositioning.
A battery-powered pulse generator sends biphasic pulses through two electrodes placed on intact skin near the painful area. The pulses recruit sensory afferents that modulate the transmission of pain signals in the spinal cord.
A contoured foam support has a recessed region aligned with the tender site. The surrounding foam spreads the load over a larger area and reduces direct pressure at the site during repositioning.
A shallow array of hollow needles makes physical channels through the stratum corneum. A metering chamber drives the solution through the needle lumens and into the superficial dermis.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An outpatient rehabilitation formulation retains the anti-inflammatory analgesic, muscle relaxant, neuropathic analgesic, and local anesthetic for use at a site of nonsurgical musculoskeletal pain. The four agents are dispersed in a hydroxyethyl cellulose gel containing propylene glycol as a skin penetration enhancer. The gel spreads over intact skin near the affected joint, and the vehicle releases the dispersed agents at the skin surface.
Diclofenac sodium replaces ketoprofen as the anti-inflammatory analgesic, alongside baclofen, amitriptyline, and lidocaine. A hydroxypropyl cellulose network thickens a water, ethanol, and propylene glycol vehicle that holds the four agents. Ethanol and propylene glycol enhance skin penetration, and the polymer limits runoff after spreading.
A suspension of phosphatidylcholine vesicles replaces the emulsion carrier and retains the anti-inflammatory analgesic, muscle relaxant, neuropathic analgesic, and local anesthetic. Water-soluble forms are introduced during hydration of the lipid film, and lipid-soluble forms are incorporated into the film before hydration. The vesicle suspension is blended into a hydroxyethyl cellulose gel, and the phospholipids interact with the outer skin layer as the agents partition out of the vehicle.
The same batch containing all four active agents and the penetration-enhancing carrier is spread through 100 and 200 micrometer spacers over separate 4 square centimeter test membranes. The spacers produce nominal wet film volumes of 40 and 80 microliters. The two films use the same membrane material and receptor fluid so that the measured release profiles reflect the difference in applied film thickness.
A flexible reservoir patch holds the four active agents in a propylene glycol-containing gel between a sealed backing and a skin-facing porous membrane. A perimeter adhesive ring secures the patch to intact skin and keeps the adhesive separate from the gel reservoir. The agents diffuse through the membrane to the skin, where the carrier promotes penetration.
A positive-displacement pump transfers the mixed four-agent formulation and its penetration-enhancing carrier from an agitated vessel into single-use containers on a load cell. The controller tares each empty container, fills rapidly to a preset fraction of the target mass, and then pulses the pump to reach the target. The controller records each net fill mass and diverts containers outside the configured mass tolerance.
Diclofenac sodium is dissolved in the aqueous phase of a carbomer gel. Diclofenac inhibits cyclooxygenase activity and reduces prostaglandin production in exposed tissue.
Micronized baclofen is dispersed in a hydrated hydroxyethyl cellulose gel. Baclofen activates gamma-aminobutyric acid type B receptors and reduces excitatory transmission in spinal motor pathways.
Lidocaine base is dissolved in the oil phase of an oil-in-water cream. Lidocaine blocks voltage-gated sodium channels in exposed sensory nerve fibers and suppresses impulse conduction.
The carrier uses water, ethanol, and propylene glycol as a mixed solvent system. Ethanol alters lipid packing in the stratum corneum, and propylene glycol maintains drug solubility as ethanol evaporates.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic.A · US 9,707,197 B2 · abstract
According to further aspects of the present teaching, the topical treatment medicinal composition further includes a topical nonsteroidal anti-inflammatory drug, wherein the nonsteroidal anti-inflammatory drug is selected from the group consisting of diclofenac/misoprostol systemic, capsaicin/diclofenac topical, trolamine salicylate, naproxen, ibuprofen, aspirin and combinations thereof.B · US 11,471,427 B1 · ¶ 37
The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic.A · US 9,707,197 B2 · abstract
The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic.A · US 9,707,197 B2 · abstract
The Henna plant contains a chemical compound 2-hydroxy-1,4-naphthoquinone within its leaves. This compound is believed to possesses natural analgesic and skin cooling properties that when combined with other natural and synthetic compounds creates an efficacious and safe, non-opioid topical therapy for those suffering from HFS as well as other painful skin diseases and neurological conditions.B · US 11,471,427 B1 · ¶ 64
While usually palliative care or supportive treatment along with topical anesthetics is used to treat HFS, a study has found that topically applying Henna to the affected areas can be effective in providing relief from this side-effect.[6]B · US 11,471,427 B1 · ¶ 22
An empty cell means only that no passage was reproduced there.
Treatment of musculoskeletal pain using anti-inflammatory drugs, such as non-steroidal anti-inflammatory drugs or NSAIDs, is not always effective.A · US 9,707,197 B2 · ¶ 3
Forming another aspect of the invention, the neuropathic analgesic can be Amitriptyline, the muscle relaxant can be Baclofen, the anesthetic can be Lidocaine and the anti-inflammatory analgesic can be Ketoprofen.A · US 9,707,197 B2 · ¶ 9
The medicinal composition may also be used for treating other skin ailments.B · US 11,471,427 B1 · ¶ 1
Frustrated with the lack of options and unsatisfied with the relief she felt with prescription and OTC remedies, we created a topical formulation which, when applied once a day, cooled the skin and routinely reduced her pain score by 75% over the span of 24 weeks.B · US 11,471,427 B1 · ¶ 3
patent.fyi, US 2026/0355138 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355138/, SHA-256 8da963b78f092a992866d878fb1ba0d68ab9be088e4703f23212d32748fd6f3f